CHICAGO, Sept. 18, 2007 (PRIME NEWSWIRE) -- VIRxSYS Corporation, a privately held company developing genetic therapies for HIV and genetic diseases, announced today the presentation of a new analysis of safety data from Phase I and Phase II studies of VRX496, their proprietary HIV-based lentiviral vector gene delivery system, at the American Society for Microbiology's 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. VIRxSYS has now accumulated 65 patient-years of data on human administration of VRX496. Five patients in Phase I have been followed for three to four years without serious adverse events. In Phase II, 24 patients have been followed for nine months to one year, and safety monitoring is ongoing.
